Profile to raise $40 million for smart inhaler:
This article was originally published in Clinica
Profile Therapeutics plans to raise £25.5 million ($40 million) on the London Stock Exchange. The Bognor Regis, Sussex-based company is developing inhaled drug delivery systems, based around its Adaptive Aerosol Delivery technology, which produces reproducible and precise doses by adapting to patients' breathing patterns. The company, which began as an inhaler distributor in 1977, launched its first product, the HaloLite system, in 1998. Its present turnover is around £10 million and the flotation, due for March 31, values the company at £81 million.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.